ALAS1 and anhaptoglobinemia: For example, givosiran is a GalNAc-conjugated siRNA therapeutic agent targeting 5′-aminolevulinate synthase 1 (ALAS1) that is approved for the treatment of acute hepatic porphyria (AHP) in the United States and in the European Union [127].